Progress in the study of cryoablation-induced immune effects and combined immunotherapy

Corresponding author: Lili, qgyzlili@163.com

DOI: 10.12201/bmr.202503.00061

•  

  Abstract: Cryoablation is a minimally invasive tumor therapy for patients with early-stage tumors as well as those with advanced tumors that cannot be surgically removed. In addition to causing necrosis and apoptosis of tumor tissues, cryoablation promotes the release of tumor self-antigens into the bloodstream, including damage-associated molecular patterns (DAMP) and tumor-specific antigens, which activate the host immune system to trigger an anti-tumor immune response, which may lead to primary tumor regression. However, this distant effect is not effective in inhibiting the growth of metastatic tumors. In recent years, immunotherapy is one of the most important means of tumor treatment, which can effectively activate the patients own immune system. Due to the complexity of the tumor immune microenvironment, immune-related adverse events, and the multifactorial mechanisms affecting the immune response, immunotherapeutic monotherapies have not yet demonstrated satisfactory efficacy in some clinical applications. This article reviews the progress of cryoablation-induced immune effects and combined immunotherapy.

  Key words: cryoablation; immune mechanism; immunotherapy; combination therapy

  Submit time: 20 March 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• liuyaru, shihao, sunguanqun, dongjingjing, yehanfeng, zhengleyi, sundan. Design and Research of Intelligent Remote Management System for Tumor Patients after Immunotherapy. 2022. doi: 10.12201/bmr.202206.00007

  Clinical research progress of PD-1/PD-L1 inhibitor induction therapy in unresectable stage III non-small-cell lung cancer. 2025. doi: 10.12201/bmr.202501.00025

  Yadian Lei, Haiyan Wang. The Impact of the Tumor Immune Microenvironment on T Cell Function: Focusing on the Limitations of ICB and Combined Treatment Strategies. 2024. doi: 10.12201/bmr.202412.00083

  Bao Kaiwen. Research progress on DNA damage and immune response in autoimmune diseases. 2024. doi: 10.12201/bmr.202410.00007

  Zhulei. Research Progress on Drug-induced Liver Injury with Immune Characteristics. 2025. doi: 10.12201/bmr.202504.00001

  Chen Lili. Study on the immune regulatory mechanism of ω－3PUFA in premature infants with brain injury. 2024. doi: 10.12201/bmr.202408.00011

  Hui Danni, Han Mengjie, Li Erle, Xue Yajuan. Review on the immunotherapy in allergic rhinitis. 2024. doi: 10.12201/bmr.202410.00042

  WANG Guangyan, NAN Shuang. Mendelian Randomization Study on Cervical Cancer and Immune Cell Phenotypes. 2024. doi: 10.12201/bmr.202412.00050

  QIAN Yun. Adverse events associated with immune checkpoint inhibitors: clinical manifestations and mechanisms. 2025. doi: 10.12201/bmr.202502.00010

  ChenYu, libowen, yangjinhua, liuyang, weiyunwei. Research progress and prospect of targeted therapy of microflora in hepatocellular carcinoma. 2024. doi: 10.12201/bmr.202412.00033

• ID	Submit time	Number	Download
  1	2025-02-18	bmr.202503.00061V1	Download

• Public  Anonymous  To author only Submit Comments